1 Li, V.S. et al. Wnt signaling through inhibition of β-catenin degradation in an intact Axin1 complex. Cell 149, 1245–1256 (2012).

2 Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012).

3 Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069–1075 (2008).

4 Grasso, C.S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239–243 (2012).

5 Jia, D. et al. Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex. Hepatology 60, 1686–1696 (2014).

6 Jones, D.T. et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 488, 100–105 (2012).

7 Kandoth, C. et al. Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67–73 (2013).

8 Reya, T. & Clevers, H. Wnt signalling in stem cells and cancer. Nature 434, 843–850 (2005).

9 Harada, N. et al. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J. 18, 5931–5942 (1999).

10 Kahn, M. Can we safely target the WNT pathway? Nat. Rev. Drug Discov. 13, 513–532 (2014).

11 Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339 (2013).

12 Sato, N., Meijer, L., Skaltsounis, L., Greengard, P. & Brivanlou, A.H. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat. Med. 10, 55–63 (2004).

13 Fuerer, C. & Nusse, R. Lentiviral vectors to probe and manipulate the Wnt signaling pathway. PLoS One 5, e9370 (2010).

14 Heckl, D. et al. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat. Biotechnol. 32, 941–946 (2014).

15 Chan, T.A., Wang, Z., Dang, L.H., Vogelstein, B. & Kinzler, K.W. Targeted inactivation of CTNNB1 reveals unexpected effects of beta-catenin mutation. Proc. Natl. Acad. Sci. USA 99, 8265–8270 (2002).

16 Hudson, C., Kawai, N., Negishi, T. & Yasuo, H. β-Catenin-driven binary fate specification segregates germ layers in ascidian embryos. Curr. Biol. 23, 491–495 (2013).

17 Schneider, S.Q. & Bowerman, B. β-Catenin asymmetries after all animal/vegetal- oriented cell divisions in Platynereis dumerilii embryos mediate binary cell-fate specification. Dev. Cell 13, 73–86 (2007).

18 Watanabe, K. et al. Integrative ChIP-seq/microarray analysis identifies a CTNNB1 target signature enriched in intestinal stem cells and colon cancer. PLoS One 9, e92317 (2014).

19 Su, L.K. et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256, 668–670 (1992).

20 Theodos, C.M., Griffiths, J.K., D'Onfro, J., Fairfield, A. & Tzipori, S. Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Antimicrob. Agents Chemother. 42, 1959–1965 (1998).

21 Bajaj, J., Zimdahl, B. & Reya, T. Fearful symmetry: subversion of asymmetric division in cancer development and progression. Cancer Res. 75, 792–797 (2015).

22 Su, Y. et al. APC is essential for targeting phosphorylated β-catenin to the SCFbeta-TrCP ubiquitin ligase. Mol. Cell 32, 652–661 (2008).

23 Lomenick, B. et al. Target identification using drug affinity responsive target stability (DARTS). Proc. Natl. Acad. Sci. USA 106, 21984–21989 (2009).

24 Wienken, C.J., Baaske, P., Rothbauer, U., Braun, D. & Duhr, S. Protein-binding assays in biological liquids using microscale thermophoresis. Nat. Commun. 1, 100 (2010).

25 Martinez Molina, D. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84–87 (2013).

26 Fuhrmann, J., Clancy, K.W. & Thompson, P.R. Chemical biology of protein arginine modifications in epigenetic regulation. Chem. Rev. 115, 5413–5461 (2015).

27 Lewallen, D.M. et al. Chemical proteomic platform to identify citrullinated proteins. ACS Chem. Biol. 10, 2520–2528 (2015).

28 Slade, D.J. et al. Protein arginine deiminase 2 binds calcium in an ordered fashion: implications for inhibitor design. ACS Chem. Biol. 10, 1043–1053 (2015).

29 Bang, H. et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum. 56, 2503–2511 (2007).

30 Ashiru, O., Howe, J.D. & Butters, T.D. Nitazoxanide, an antiviral thiazolide, depletes ATP-sensitive intracellular Ca2+ stores. Virology 462–463, 135–148 (2014).

31 Huels, D.J. et al. E-cadherin can limit the transforming properties of activating β-catenin mutations. EMBO J. 34, 2321–2333 (2015).

32 Anderson, V.R. & Curran, M.P. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs 67, 1947–1967 (2007).

33 Di Santo, N. & Ehrisman, J. A functional perspective of nitazoxanide as a potential anticancer drug. Mutat. Res. 768, 16–21 (2014).

34 Hsu, K.W. et al. The activated Notch1 receptor cooperates with alpha-enolase and MBP-1 in modulating c-myc activity. Mol. Cell. Biol. 28, 4829–4842 (2008).

35 Senkowski, W. et al. Three-dimensional cell culture-based screening identifies the anthelmintic drug nitazoxanide as a candidate for treatment of colorectal cancer. Mol. Cancer Ther. 14, 1504–1516 (2015).

36 Rossignol, J.F., Elfert, A., El-Gohary, Y. & Keeffe, E.B. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 136, 856–862 (2009).

37 Yue, X. et al. Hepatitis B virus-induced calreticulin protein is involved in IFN resistance. J. Immunol. 189, 279–286 (2012).

38 Korba, B.E., Elazar, M., Lui, P., Rossignol, J.F. & Glenn, J.S. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob. Agents Chemother. 52, 4069–4071 (2008).

39 Ramírez, G., Valck, C., Ferreira, V.P., López, N. & Ferreira, A. Extracellular Trypanosoma cruzi calreticulin in the host-parasite interplay. Trends Parasitol. 27, 115–122 (2011).

40 Müller, J. et al. Thiazolides inhibit growth and induce glutathione-S-transferase Pi (GSTP1)-dependent cell death in human colon cancer cells. Int. J. Cancer 123, 1797–1806 (2008).

41 Fan-Minogue, H. et al. A c-Myc activation sensor-based high-throughput drug screening identifies an antineoplastic effect of nitazoxanide. Mol. Cancer Ther. 12, 1896–1905 (2013).

42 Brockmann, A. et al. Structure-function relationship of thiazolide-induced apoptosis in colorectal tumor cells. ACS Chem. Biol. 9, 1520–1527 (2014).

43 Stadler, S.C. et al. Dysregulation of PAD4-mediated citrullination of nuclear GSK3β activates TGF-β signaling and induces epithelial-to-mesenchymal transition in breast cancer cells. Proc. Natl. Acad. Sci. USA 110, 11851–11856 (2013).

44 Deplus, R. et al. Citrullination of DNMT3A by PADI4 regulates its stability and controls DNA methylation. Nucleic Acids Res. 42, 8285–8296 (2014).

45 Vossenaar, E.R., Zendman, A.J., van Venrooij, W.J. & Pruijn, G.J. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. BioEssays 25, 1106–1118 (2003).

46 Wu, H.Y. et al. Structural basis of antizyme-mediated regulation of polyamine homeostasis. Proc. Natl. Acad. Sci. USA 112, 11229–11234 (2015).

47 Van Lidth de Jeude, J.F., Vermeulen, J.L., Montenegro-Miranda, P.S., Van den Brink, G.R. & Heijmans, J. A protocol for lentiviral transduction and downstream analysis of intestinal organoids. J. Vis. Exp. 2015, e52531 (2015).